The survival of biotechnology firm Novavax hangs in the balance as activist investor Shah Capital escalates pressure on the company’s leadership. Having increased its stake to approximately 8.3 percent, the investment firm is now demanding an immediate exploration of strategic alternatives, including a complete sale of the company, and threatens a proxy battle if the board fails to act.
Financial Performance Fuels Activist Demands
Recent quarterly results underscore the company’s deteriorating financial position, providing ammunition for Shah Capital’s campaign:
* Third-quarter revenue reached just $70 million
* Net losses exceeded $202 million
* Despite achieving $225 million in milestone payments from partner Sanofi
The partnership with Sanofi, while formally progressing, has failed to deliver commercial success. Investor concerns intensified further when Novavax delayed its profitability forecast to 2028.
Market Share Collapse Highlights Competitive Struggle
Novavax’s protein-based COVID-19 vaccine has captured a mere 0.8 percent market share during the 2025-26 vaccination year. With only 120,000 doses administered compared to 14.5 million doses from competitors, the commercial performance has been devastating.
Should investors sell immediately? Or is it worth buying Novavax?
In a sharply worded letter to the board of directors, Shah Capital accused Novavax management and partner Sanofi of either “profound incompetence” or deliberate underperformance. The investor insists on establishing a special committee immediately to evaluate all strategic options.
Stock Market Reaction Reflects Deep Concerns
The company’s stock market performance mirrors its operational challenges. Shares are trading significantly below key moving averages, displaying clear sell signals across both short and long-term technical indicators. The technical outlook remains tense while fundamental uncertainty grows amid increasing activist pressure.
The coming four months appear decisive. Either the board will comply with demands for a strategic review, or Novavax faces a control contest that could substantially increase stock volatility. The stage is set for a potential final showdown that will determine the company’s future.
Ad
Novavax Stock: Buy or Sell?! New Novavax Analysis from December 28 delivers the answer:
The latest Novavax figures speak for themselves: Urgent action needed for Novavax investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 28.
Novavax: Buy or sell? Read more here...
